These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

12248 related articles for article (PubMed ID: 11596037)

  • 1. Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.
    Joukhadar C; Klein N; Mader RM; Schrolnberger C; Rizovski B; Heere-Ress E; Pehamberger H; Strauchmann N; Jansen B; Müller M
    Cancer; 2001 Oct; 92(8):2190-6. PubMed ID: 11596037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
    Chabot GG; Flaherty LE; Valdivieso M; Baker LH
    Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.
    Breithaupt H; Dammann A; Aigner K
    Cancer Chemother Pharmacol; 1982; 9(2):103-9. PubMed ID: 7172404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
    Agarwala SS; Kirkwood JM
    Oncologist; 2000; 5(2):144-51. PubMed ID: 10794805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
    Brendel E; Ludwig M; Lathia C; Robert C; Ropert S; Soria JC; Armand JP
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):53-61. PubMed ID: 20821331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
    Treudler R; Georgieva J; Geilen CC; Orfanos CE
    J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
    Kantrowitz-Gordon I; Hays K; Kayode O; Kumar AR; Kaplan HG; Reid JM; Safgren SL; Ames MM; Easterling TR; Hebert MF
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):455-460. PubMed ID: 29305638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
    J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dacarbazine: deticene].
    Quéreux G; Brocard A; Dréno B
    Ann Dermatol Venereol; 2007 Dec; 134(12):1001-3. PubMed ID: 18166926
    [No Abstract]   [Full Text] [Related]  

  • 13. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
    Lev DC; Onn A; Melinkova VO; Miller C; Stone V; Ruiz M; McGary EC; Ananthaswamy HN; Price JE; Bar-Eli M
    J Clin Oncol; 2004 Jun; 22(11):2092-100. PubMed ID: 15123733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography.
    Fiore D; Jackson AJ; Didolkar MS; Dandu VR
    Antimicrob Agents Chemother; 1985 Jun; 27(6):977-9. PubMed ID: 4026274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of brain metastases of malignant melanoma with temozolomide.
    Biasco G; Pantaleo MA; Casadei S
    N Engl J Med; 2001 Aug; 345(8):621-2. PubMed ID: 11529230
    [No Abstract]   [Full Text] [Related]  

  • 16. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
    Teimouri F; Nikfar S; Abdollahi M
    Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
    Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
    J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
    Busch C; Geisler J; Knappskog S; Lillehaug JR; Lønning PE
    J Invest Dermatol; 2010 Oct; 130(10):2514-6. PubMed ID: 20505745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 613.